boston scientif corp engag develop
manufactur market medic devic
use broad rang intervent medic
specialti compani product technolog
use diagnos treat wide rang medic
vascular urolog women health chronic pain
condit compani headquart natick
reason report
estim chang analysi sales/earn
reiter invest rate price target
share follow compani uncharacterist shortfal
opinion core tenant stori remain unchang
see potenti annual revenu growth margin
expans improv rel prevail level
compani face number previous unforeseen headwind
loss vagin mesh sale paxlitaxcel concern lost men health
sale due steril underli busi continu exhibit
best class organ growth outlook stand enhanc
acceler growth core product plan new product
launch throughout cy pend btg acquisit
close result reiter invest rate
price target share opinion stori remain
much on-track
maintain price price target
share remain unchang recal price target assum
ev/ebitda multipl non-gaap
earn multipl
chang estim fine tune former
revenu non-gaap earn estim billion
billion per share respect figur
convers maintain revenu non-gaap
earn estim exclud pend btg acquisit
billion per dilut share earn
estim revis summar tabl left
guidanc rang revis rang
increas lower-bound non-gaap cash earn
guidanc revis rang per share
growth guidanc non-gaap cash earn
guidanc rang per share versu pre-cal
consensu estim per share
valuat summari share current valu
revenu ebitda cash
earn multipl figur versu slower grow
industri peer trade averag like multipl
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
summari oper review report sale billion pre-cal consensu billion
oper basi organ basi report intern cardiolog revenu
million increas report led structur heart mid-teen growth complex pci offset weak
de importantli continu forecast compani track achiev structur heart revenu guidanc
million million led watchman acur lotu edg sentinel peripher intervent
revenu million increas report driven domest launch eluvia intervent oncolog
core balloon product result compani cardiolog busi gener million revenu pre-
call consensu million endoscopi revenu million increas report basi led
compani infect prevent biliari franchis urolog pelvic health revenu million increas
report driven emerg market expans increas patient awar lithovu single-us digit
ureteroscop result compani surg segment report revenu million pre-cal consensu
million cardiac rhythm manag revenu million declin report due
fx headwind off-set strong uptak resont platform heartlog emblem s-icd
growth devic replac cycl in-lin expect electrophysiolog revenu million increas
report led rhythmia hdx platform strong uptak directsens cathet europ initi
adopt lumipoint softwar neuromodul revenu million increas report driven
wavewrit system continu intern momentum vercis db expans vercis
launch cartesia direct lead mri label expect result compani rhythm
neuro segment report revenu million pre-cal consensu million
report adjust gross margin year year corpor guidanc
result less favor mix lower sale volum mesh inventori reserv unfavor manufactur
varianc bsx cardiovascular busi report adjust oper margin decreas year
year medsurg busi report adjust oper margin year year
compani rhythm neuro busi report adjust oper margin year
year result report adjust oper margin year year lastli report
adjust tax rate compani guidanc due higher-than-expect benefit stock
base compens account result compani report non-gaap cash earn inclus
charg surgic mesh per share pre-cal consensu per share
free oper period gener approxim million adjust free cash
flow versu million prior year period moreov compani continu forecast adjust free cash flow
billion follow close pend btg acquisit continu plan alloc
billion reduc corpor debt follow month bring compani leverag ratio
ebitda within two year compani guidanc impli annual growth billion
continu reflect overal strength oper model
divers new product pipelin lend confid sustain peer growth remain on-track
launch multipl new product lend addit support compani abil either sustain
enhanc prevail rate growth profit notabl continu anticip launch wathcman
laac europ japan earli stage control roll-out lotu edg valv system
 addit compani track launch exalt-d single-us dispos duodenoscop
stand lend support continu market rate endoscopi growth also encourag previous
mention launch vercis db cartesia direct lead expect mri label
oper period lastli compani urology/pelv busi stand benefit four plan
new product launch stone plan new product cadenc taper enter line extens
synergi de ranger sfa dcb new icm monitor dx forc sens cathet expand db platform
next-gen spyglass visul system next gen lithovu ureteroscop slate launch addit
number offer simpli put new product pipelin remain replet potenti
detail look chang corpor guidanc lower upper-bound revenu guidanc
rang billion billion revis rang billion billion pre-cal
consensu billion impli organ revenu growth specif compani experienc
lighter sale oper period due regulatori headwind relat paclitaxel reduct eluvia
revenu expect transvagin mesh million impact year steril men
lead decreas organ revenu guidanc convers modestli increas lower-bound
compani non-gaap cash earn guidanc rang per share revis rang
per share specif compani forecast improv adjust tax rate vs
geograph mix favor stock base compens account howev
reduct eluvia relat revenu growth guidanc owe on-going paxlitaxel related-concern expect
off-set tax gain compani regain balanc year lost due
charg relat mesh market oper period establish revenu growth rang
report basi impli sale rang billion billion pre-cal consensu
billion cash ep rang pre-cal consensu addit compani expect
foreign exchang headwind approxim million million revenu oper
period million million neutral earn quarter full year
million except per share data
research develop
sale market administr
incom prior tax
top-lin pressur unforeseen
lower forecast gross profit due
unfavor manufactur
tax provis benefit favor stock
mesh
million except per share data
note street estim compris consensu includ contribut pend btg acquisit
compani document stephen inc estim
becton dickinson compani
note data reflect stephen estim other consensu
stephen inc estim
compani document
consolid statement incom
million except per share data
good sold
research develop
sale market administr
fiscal period
fiscal period
fiscal period
incom prior tax
weight averag share issu outstand
compani report stephen inc estim
becton dickinson compani
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
